| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients | Sarah Karlin-Smith | 07/02/20 | National |
| Chiesi Licenses Bioasis Tech to Tackle Brain Symptoms of Rare Diseases | Sarah de Crescenzo | 07/01/20 | Boston |
| Roche Gets FDA OK for Injectable Version of Breast Cancer Drug | Sarah de Crescenzo | 06/29/20 | San Diego |
| FDA Says “No” to Intercept Pharma’s NASH Drug, Asks for More Data | Frank Vinluan | 06/29/20 | New York |
| With Peanut Patch in FDA Purgatory, DBV Plans Layoffs to Stretch Cash | Sarah de Crescenzo | 06/26/20 | National |
| Eye Inflammation Dooms AbbVie Wet AMD Drug to an FDA Rejection | Frank Vinluan | 06/26/20 | National |
| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy | Frank Vinluan | 06/25/20 | Philadelphia |
| AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis | Frank Vinluan | 06/24/20 | National |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Timing Is an Essential Element of Cell & Gene Therapy Product Development | Sarah de Crescenzo | 06/19/20 | Philadelphia |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel | Frank Vinluan | 06/16/20 | Philadelphia |
| Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug | Sarah de Crescenzo | 06/15/20 | National |
| FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19 | Sarah de Crescenzo | 06/15/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
| Reata Bags $350M as It Preps Rare Chronic Kidney Disease Drug for FDA | Sarah de Crescenzo | 06/11/20 | Texas |
| Moderna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine | Frank Vinluan | 06/11/20 | Boston |
| Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes | Frank Vinluan | 06/11/20 | Boston |
| Merck’s Keytruda Fails Pivotal Bladder Cancer Study, Sinks First-Line Hopes | Frank Vinluan | 06/10/20 | New York |
| Melinta Expands Antibiotics Lineup With $39M Tetraphase Acquisition | Frank Vinluan | 06/09/20 | New York |
| CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain” | Frank Vinluan | 06/09/20 | Boston |
| Akouos Aims for an IPO to Advance Hearing Loss Gene Therapy to Clinic | Frank Vinluan | 06/08/20 | Boston |
| Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug | Frank Vinluan | 06/05/20 | New York |
| Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More | Frank Vinluan | 06/05/20 | National |
| Regeneron Pays Intellia $100M to Add Hemophilia to CRISPR R&D Pact | Frank Vinluan | 06/01/20 | New York |
| After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Frank Vinluan | 05/29/20 | Boston |
| Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | Sarah de Crescenzo | 05/29/20 | National |
| Variant Emerges With $16M to Find “Outlier Humans” to Reveal New Drugs | Sarah de Crescenzo | 05/28/20 | Seattle |
